Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 4/20 | 0.65 |
| ▸ | NPY2R | P49146 | 7/20 | 0.63 |
| ▸ | NPY4R | P50391 | 7/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.63 |
| ▸ | NPY1R | P25929 | 5/20 | 0.63 |
| ▸ | REN | P00797 | 3/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isracidin SCHEMBL29668326 | 0.87 | NPY2R (0.70) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30294080 | 0.86 | OPRD1 (0.60) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29358935 | 0.86 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30300729 | 0.85 | REN (0.63) | NPY2RNPY4RNPY5RNPY1RREN | |
| Piscidin 3 SCHEMBL29810102 | 0.85 | VIPR2 (0.66) | — | |
| SCHEMBL29352518 | 0.84 | RAMP3 (0.65) | NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29356071 | 0.84 | RAMP3 (0.65) | NPY2RNPY4RNPY5RNPY1R | |
| Temporin A SCHEMBL29385766 | 0.84 | OPRD1 (0.60) | TFPI | |
| Temporin A SCHEMBL13613777 | 0.84 | OPRD1 (0.60) | TFPI | |
| SCHEMBL31129133 | 0.84 | OPRD1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | claimed |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | claimed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | claimed |
| US-20250346603-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIKAVATION THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-08-29 | — | — | US | claimed |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | claimed |
| US-11912722-B2 | Tricyclic heteroaryl compounds as sting activators | INCYTE CORPORATION (US) | 2024-02-27 | — | — | US | claimed |
| US-20240034734-A1 | TETRACYCLIC COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2024-02-01 | — | — | US | claimed |
| US-20240025900-A1 | TETRACYCLIC COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2024-01-25 | — | — | US | claimed |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | claimed |
| WO-2023230262-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2023145699-A1 | INFRARED ABSORBING COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, INFRARED SENSOR, AND CAMERA MODULE | 富士フイルム株式会社 | 2023-08-03 | — | — | WO | claimed |
| WO-2023145700-A1 | INFRARED ABSORBING COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, INFRARED SENSOR, AND CAMERA MODULE | 富士フイルム株式会社 | 2023-08-03 | — | — | WO | claimed |
| US-20230114765-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-04-13 | — | — | US | claimed |
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20230114765-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3802534-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS | INCYTE CORP (US) | 2022-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600717-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | TFPI 3915/4885NPY2R 3627/4885NPY4R 4074/4885 |
| US-20230114765-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | TFPI 624/4885NPY2R 4871/4885NPY4R 4883/4885 |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | TFPI 1437/4885NPY2R 4859/4885NPY4R 4881/4885 |
| US-20240025900-A1 | TETRACYCLIC COMPOUNDS AS DGK INHIBITORS | DGKA, DGKG, DGKI | TFPI 635/4885NPY2R 4850/4885NPY4R 4838/4885 |
| US-20250346603-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | TFPI 1111/4885NPY2R 4873/4885NPY4R 4871/4885 |
| US-20240034734-A1 | TETRACYCLIC COMPOUNDS AS DGK INHIBITORS | DGKA, DGKG, DGKI | TFPI 635/4885NPY2R 4850/4885NPY4R 4838/4885 |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | TFPI 1244/4885NPY2R 3476/4885NPY4R 3231/4885 |
| US-11912722-B2 | Tricyclic heteroaryl compounds as sting activators | STING1, MAVS, IRF3 | TFPI 438/4885NPY2R 3952/4885NPY4R 4103/4885 |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | PDXK, PCK1, HIPK1 | TFPI 1139/4885NPY2R 4320/4885NPY4R 4431/4885 |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | KRAS, HRAS, NRAS | TFPI 1717/4885NPY2R 4784/4885NPY4R 4847/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | TFPI 1263/4885NPY2R 4830/4885NPY4R 4873/4885 |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | DGKB, DGKA, NR2C2 | TFPI 4399/4885NPY2R 1068/4885NPY4R 3301/4885 |
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | DGKB, DGKA, DGKK | TFPI 4314/4885NPY2R 1452/4885NPY4R 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.